Eisai, Biogen say lecanemab received Priority Review status in Japan
PremiumThe FlyEisai, Biogen say lecanemab received Priority Review status in Japan
2y ago
Eisai, Biogen: EMA accepts MAA for lecanemab for early Alzheimer’s disease
Premium
The Fly
Eisai, Biogen: EMA accepts MAA for lecanemab for early Alzheimer’s disease
2y ago
Catalyst Pharmaceuticals completes acquisition of U.S. rights to FYCOMPA CII
Premium
The Fly
Catalyst Pharmaceuticals completes acquisition of U.S. rights to FYCOMPA CII
2y ago
Biogen, Eisai May Have an Alzheimer’s Beater on Their Hands
PremiumMarket NewsBiogen, Eisai May Have an Alzheimer’s Beater on Their Hands
2y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100